Testing a new blood cancer medication combined with standard treatments

This research study is testing whether ABL001, a new investigational medication, is safe and works well when combined with three FDA-approved drugs (dasatinib, prednisone, and blinatumomab) that are already standard treatment for certain blood cancers. Researchers want to find the right dose of this medication and learn whether adding it to your regular treatment helps improve outcomes for people with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast crisis.

While the three standard drugs are proven to work, researchers have preliminary evidence that adding this new medication might make treatment more effective. This study will find out if the medication is safe to use with these standard treatments and whether it helps patients with these aggressive blood cancers.